
AdvaMed Response to House Privacy Working Group RFI
AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.
AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.
AdvaMed urges DOJ to remove outdated rules that block medtech innovation and limit access to lifesaving technology.
AdvaMed urges OIG to modernize Anti-Kickback Statute safe harbors and issue a new fraud alert to support value-based care and expand access to medical technologies.
AdvaMed®, the world’s leading medtech trade association, communicated to Centers for Medicaid & Medicare Services (CMS) recommendations regarding administration of the Open Payments program.
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA).
AdvaMed® responded to HHS OIG’s annual solicitation of proposals for new and modified safe harbors and special fraud alerts.
Lucy Fraiser, Ph.D., a board-certified toxicologist, recently responded in a letter to the editor of Modern Healthcare about the publication’s recent coverage of the EPA’s work on ethylene oxide.
AdvaMed® submitted comments to CMS on the CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule.
AdvaMed® submitted comments to CMS on the Calendar Year 2023 Physician Fee Schedule (PFS) proposed rule.
AdvaMed® submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.